Health care special purpose acquisition companies in 2020-2021 represented a temporary market inefficiency that enabled weaker companies to bypass traditional due diligence and ultimately led to failures.
|Articles|March 1, 1997
Supplements and Featured Publications
- Integrating Risk Factor Management of Coronary Heart Disease into Managed Care
- Volume 3
- Issue 3 Suppl
Major Clinical Trials: Pharmacologic Therapy in Higher Risk Patients
Author(s)Sidney C. Smith, Jr, MD
Advertisement
Articles in this issue
over 29 years ago
Goals and Objectivesover 29 years ago
Introductionover 29 years ago
Risk-Factor Management in Women and Other Special Patientsover 29 years ago
Risk Factor Management: Exploring the Boundariesover 29 years ago
CME Quizover 29 years ago
BibliographyAdvertisement
Related to this article
Machine learning prediction of procalcitonin positivity using inexpensive routine laboratory tests may reduce procalcitonin test volume and support diagnostic stewardship.
After Pennsylvania began rewarding Medicaid managed care plans for increasing well-child visits among Black infants, rates did not change significantly overall but varied by region.
Greater 340B activity—measured by county-level hospital child sites and contract pharmacy arrangements—was associated with significantly higher county-level total and out-of-pocket health care spending.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
4
Early-Onset Cancers Often Found Late as Screening Gaps Persist
5